A Study of REGN7544 for the Treatment in Adult Patients With Sepsis-Induced Hypotension
← catalyst calendarSponsored by Regeneron Pharmaceuticals (industry) · REGN — their whole pipeline →.
Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
76actual
Sites
29
Countries
France, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-05-05 | actual | When the study began enrolling |
| Primary completion | 2026-02-01 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-04-28 | actual | The whole study's end, after follow-up |
| First posted | 2024-09-23 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-20 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Sepsis-Induced Hypotension
Interventions
- Drug: REGN7544
- Drug: PB
Primary outcome
what the primary-completion date above is the date OFCumulative vasopressor dose
measured Through 72 Hours
Permalink · REGN's whole pipeline · Catalyst calendar · Every registered study · What changed